Simultaneous Estimation of Racecadotril and Ofloxacin by Reverse Phase High Performance Liquid Chromatography Method in Pharmaceutical Dosage Forms. by Gupta, Komal et al.
Gupta et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):165-170  
ISSN: 2250-1177                                                                                  [165]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.08.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Simultaneous Estimation of Racecadotril and Ofloxacin by Reverse Phase 
High Performance Liquid Chromatography Method in Pharmaceutical 
Dosage Forms. 
Gupta Komal, Sharma Deepika, Chawla Pooja * 
Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga-142001, India 
 
ABSTRACT 
Background: Racecadotril and Ofloxacin (RACIGYL- O) drug combination are used for the treatment of diarrhea. The drugs have been 
estimated individually in formulations but no method has been developed for simultaneous estimation of these two drugs as combination.  
Objective: To develop and validate a high performance liquid chromatography method for the simultaneous estimation of Racecadotril and 
Ofloxacin in tablet dosage form. 
Method: A WATERS C18 column (250 x 4.6mm, 5 μm) with mobile phase consisting of acetonitrile, methanol and water 40:40:20v/v (pH 
adjusted to 2.7 of water with ortho phosphoric acid). The flow rate was 1.0mL/min and effluents were monitored at 210nm. 
Results: The retention time of RAC and OFL was 4.666 min and 2.551 min respectively. The developed method was validated according to I CH 
guidelines with respect to specificity, linearity, accuracy, precision, robustness, Limit of Detectio n (LOD) and Limit of Quantification (LOQ). 
Conclusion: The method show good reproducibility and recovery with %RSD less than 2. So the proposed method was found to be simple, 
rapid, precise and accurate and useful for the determination of RAC and OFL in bulk and pharmaceutical dosage forms.    
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1. INTRODUCTION 
Combined dosage forms are mostly preferred these days as 
compared to single dosage forms.  Racecadotril and 
ofloxacin is available in combined pharmaceutical dosage 
form. The brand name is Racigyl-O tab containing 100 mg of 
racecadotril and 200 mg of ofloxacin used in the treatment 
of diarrhea1. Literature survey reveals that various analytical 
methods have been reported for single dosage forms. The 
present paper aims to report a simple, accurate, precise, RP-
HPLC method for estimation of racecadotril and ofloxacin in 
combined dosage forms. 
1.1 Drug profile of Racecadotril 
It is chemically known as N-[2-[(acetylthio)methyl]-1-oco-3-
phenyl-propanoyl)-glycine phenylmethyl ester, which is a 
prodrug of the enkephalinase inhibitor thiorphan2.It is a 
white powder and freely soluble in methanol and in 
dichloromethane and practically insoluble in water3. 
 
 
Fig.1. Structure ofRacecadotril2 
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1.2 Drug profile of Ofloxacin 
 
Fig. 2.Structure of Ofloxacin 
 
It is a (±)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-
oxo-2,3-dihydro-7H-pyridol(1,2,3,-de)-1,4-benzoxazine-6-
carboxylic acid4 and it is a synthetic broad spectrum 
antibacterial agent which is official in USP and BP5. It acts on 
DNA gyrase and topoisomerase IV and prevents the 
excessive supercoiling of DNA during transcription and 
translation and by inhibiting their function, it inhibits the 
normal cell divison6. It is a pale yellow or bright yellow 
crystalline powder6 and it is soluble in glacial acetic acid, 
and slightly soluble in water, dichloromethane and 
methanol3.  
2. MATERIALS AND METHODS 
2.1 Optimized chromatographic conditions  
Suitable high performance liquid chromatography equipped 
with UV-visible detector was used. HPLC (waters, 2695 
separation module) SOFTWARE (Empower, version 2.0) 
Column: Waters C18, 50mm x 4.6 
Wavelength: 210 nm 
Injection Volume: 10µL 
Column Temperature: Ambient 
Flow Rate: 1.0mL/min 
Retention time of Racecadotril and Ofloxacin are 4.666 and 
2.551 min respectively. 
2.2 Chemicals and Reagents 
Racecadotril and ofloxacin were received as gift sample from 
Leeford Healthcare Pvt. Ltd. Ludhiana and Tanishka 
Pharmaceuticals Pvt. Ltd. Baddi. The pharmaceutical 
preparations of combination of racecadotril and ofloxacin 
that is RACIGYL-O tablets (Mankind) contains 100mg of 
racecadotril and 200mg of ofloxacin was procured from local 
market. The solvents used for method development and 
validation were Methanol AR Grade, HPLC grade Methanol 
(S.D fine chemicals ltd, Mumbai, India), HPLC grade 
Acetonitrile and water for HPLC (Finar Chemicals Ltd., 
Mumbai, India).  
3. RP-HPLC method 
HPLC system of WATERS (Milford, USA) composed of 515 
HPLC pump as a solvent delivery system equipped with 
Rheodyne injection valve with a 50 μL loop. The 
chromatographic separation was performed with a WATERS, 
2695 separation module HPLC instrument equipped with 
UV-VISIBLE detector and Empower software, version 2.0. 
The Waters X bridge Stainless steel C18 column (250 mm 
×4.6 mm, 5μm) packed with ODS chemically bounded porous 
silica particles were used as stationary phase for analysis. 
BL-220H analytical balance (Shimadzu corporation, Japan), 
an ultrasonic cleaner (Frontline FS 4, Mumbai, India) and 
Digital pH meter (LI 612 pH analyzer, Elico Ltd., 
Ahmadabad), were used in the study. 
3.1 Chromatographic condition 
The optimal composition of the mobile phase was 
determined to be acetonitrile, methanol and water pH 2.7 
maintained by ortho-phosphoric acid in the ratio (40:40:20 
v/v). The mobile phase was filtered through nylon 0.22 μm 
membrane filters and was degassed to remove the air before 
use (30 min). Stock solution was prepared by dissolving RAC 
and OFL (50 mg each) that were weighed accurately and 
separately transferred into 25 mL volumetric flasks. All the 
drugs were dissolved in 25 mL of mobile phase to prepare 
standard stock solutions. After the immediate dissolution, 
the solution was sonicated and made up the volume with 
mobile phase. These standard stock solutions were observed 
to contain 2000mcg/mL of RAC and OFL. Appropriate 
volume from this solution was further diluted to get 
appropriate concentration levels according to the 
requirement. From the stock solutions, dilutions were made 
in the concentration range of 60, 80, 100, 120, 140µg/mL for 
RAC and 120, 160, 200, 240, 280µg/mL for OFL. 
3.2 Preparation of mobile phase 
Mobile phase was prepared by mixing acetonitrile (HPLC 
grade), methanol (HPLC grade) and HPLC water pH 2.7 
(40:40:20 v/v). Mixture was shaken vigorously and 
sonicated for 30 min prior to use. 
3.3 Preparation of stock solutions  
Stock solutions and sample solutions of RAC and OFL and its 
binary mixture were prepared by adding accurately weighed 
50 mg of RAC and OFL separately in 25 mL volumetric flask 
containing 15 mL of mobile phase. The flasks were then 
sonicated for 10 min and the volume was made up to the 
mark by using mobile phase. These standard stock solutions 
were containing 2000µg/mL of RAC and OFL. Stock solutions 
were used to prepare desired concentration range as per 
sample calibration range. 
3.4 Preparation of Sample solutions  
Twenty tablets were weighed and emptied. The equivalent 
weight was calculated and according to average weight, 
required drug was taken in volumetric flask to obtain 100mg 
of RAC and 200mg of OFL in single dilution i.e. according to 
the label claim of the formulation. The dilutions were first 
sonicated and then filtered through 0.22 micron filter paper. 
3.5 Preparation of Calibration curve 
The test concentrations for RAC and OFL in HPLC method 
development were found to be 100µg/mL and 200µg/mL 
respectively. The calibration curve was prepared by 
injecting the concentrations of 60-140 µg/mL of RAC and 
120-280 µg/mL of OFL in mixture solution manually in 
triplicate to the HPLC system at detection wavelength of 210 
nm. Mean of n=5 determinations was plotted as the standard 
curve. The calibration curve was tested by validating it with 
inter-day and intra-day measurements. Linearity, accuracy 
and precision were performed for both inter-day and intra-
day measurements.  
4. Method validation 
4.1 Linearity 
The methods were validated according to International 
Conference on Harmonization Q2B guidelines (2005) for 
validation of analytical procedures to determine the 
linearity, sensitivity, precision and accuracy for each analyte. 
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Calibration curves were generated with appropriate 
volumes of working standard solutions for HPLC. 
For HPLC assay method validation, the test concentrations 
were found to be 100μg/mL of RAC and 200μg/mL of OFL. 
Linearity of the proposed method was carried out by the 
preparation of 60%, 80%, 100%, 120% and 140% of RAC 
and OFL test concentration i.e.60, 80, 100, 120,140 µg/mL 
for RAC and 120, 160, 200, 240, 280 µg/mL for OFL. The 
linearity was evaluated by the least square regression 
method using weight data. 
4.2 Precision and accuracy 
Both precision and accuracy were determined with standard 
quality control samples (in addition to calibration 
standards) prepared in triplicates at different concentration 
levels covering the entire linearity range. Precision is 
defined as a degree of repeatability of an analytical method 
under normal operational conditions. The precision of the 
assay was determined by repeatability (intra-day) and 
intermediate precision (interday) and reported as %R.S.D. 
for a statistically significant number of replicate 
measurements. The intermediate precision was carried out 
by comparing the assays on 3 different days and the results 
documented as standard deviation and %R.S.D7. 
Accuracy is the percent of analyte recovered by assay from a 
known added amount. For the measurement of accuracy, 
data from nine determinations over three concentration 
levels covering the specified range were determined. The 
samples containing 80%, 100%, and 120% of test 
concentrations were spiked with 100%of standard solution 
in HPLC and percentage recovery was calculated8. 
4.3 LOD and LOQ 
The limit of detection (LOD) is defined as the lowest 
concentration of an analyte that an analytical process can 
reliably differentiate from background levels. The limit of 
quantification (LOQ) is the lowest concentration of the 
standard curve that can be measured with acceptable 
accuracy, precision and variability9. 
The LOD and LOQ were calculated as  
LOD =3.3σ/S 
LOQ =10σ/S 
Where σ is the standard deviation of the lowest standard 
concentration and S is the slope of the standard curve. 
4.4 Stability 
The stability of RAC and OFL in mobile phase was assessed 
by analyzing the sample concentrations at 1 h, 4 h, 9 h, 24 h, 
48 h and 60 h. The concentrations used in this study were 
100µg/mL for RAC and 200µg/mL for OFL prepared from 
stock solution of pure form and powdered tablet sample, 
respectively. Six replicate samples for each concentration 
were assayed at each time point. The stability was tested 
over a period of three days at room temperature. 
4.5 Robustness 
The effect of intentional variation in analytical conditions 
such as detection wavelength, mobile phase flow rate and 
mobile phase composition on the retention time and peak 
area was investigated one by one. 
5. Analysis of marketed tablets formulation by HPLC 
For the assay estimation of marketed formulation by HPLC, 
Weighed 10 tablets. Accurately weighed powder sample 
equivalent to 100mg of RAC and 200mg of OFL was 
dissolved in a 100 mL volumetric flask containing mobile 
phase. The solution was kept for sonication for 20 min, 
filtered through Whatmann filter paper No. 41. Aliquot of 
this solution was diluted to produce the concentration 
of100µg/mL for RAC and 200µg/mL for OFL. (n= 6). 
6. RESULTS AND DISCUSSION 
RP-HPLC spectrophotometric methods were developed for 
RAC and OFL which can be conveniently employed for 
routine analysis in pharmaceutical dosage forms and will 
eliminate unnecessary tedious sample preparations. The 
chromatographic conditions were optimized in order to 
provide a good performance of the assay. The retention time 
of RAC and OFL in tablets formulation were found to be 
2.551 min and 4.666 min respectively. The chromatograms 
have been shown in (Fig3 (a)). Various system suitability 
parameters are shown in Table 1. A five point calibration 
curve was constructed with working standards and was 
found linear (r2 ≥0.998 and 0.997) for RAC and OFL over 
their calibration ranges. The slopes were calculated using 
the plot of drug concentration versus area of the 
chromatogram. The developed HPLC method was accurate, 
precise, reproducible and very sensitive shown in fig (3). 
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(a) Chromatogram of RAC and OFL 
 
(b) Chromatogram of RAC at test concentration 
 
(c) Chromatogram of OFL at test concentration 
 
(d) Chromatogram of Blank 
Fig.3. (a) Chromatograms of RAC and OFL (b) Chromatogram of RAC at test concentration (c) Chromatogram of OFL at test 
concentration (d) Chromatogram of Blank 
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Table 1. System suitability studies of RAC and OFL in optimized RP-HPLC compared with USP pharmacopoeia limits. 
S.No Parameters USP Limit RAC OFL 
1. Conc. (%) - 100% 100% 
2. Retention time - 4.706 2.592 
3. Average peak area of 6 injection - 4541354.5 7830038 
4. % RSD of peak area of 6 injections ≤ 2.0 0.2008 0.480 
5. Peak Asymmetry (at 10% peak height) ≤  1.5 1.13 1.39 
6. Mean number of Theoretical plate ≥ 2000 2689 2414 
7. Final retention time - 4.666 2.551 
 
All the method validation parameters are well within the 
limits as specified in the ICH Q2B guidelines as shown in 
Table 2 and Table 3 lists the percent recovery (content 
uniformity) of all the drugs in the commercial formulations 
by HPLC methods. Moreover the %R.S.D. (less variation) 
shows good precision of both developed methods. The 
calculated LOQ and LOD concentrations confirmed that the 
methods were sufficiently sensitive. The methods were 
suitably employed for assaying all the drugs in commercial 
marketed formulation (Table 4). 
 
Table 2. Summary of the HPLC method validation 
S.No Validation parameter RAC OFL 
1. Absorption maxima, ƛ 
max
 (nm) 210 210 
2. Linearity range (µg/mL) 60-140 120-280 
3. Coefficient of determination (R
2
) 0.9989 0.9976 
4. Regression equation (y) y=43570x+173113 y=76743x+77056 
5. Slope (b) 43570 76743 
6. Intercept (a) 173113 77056 
7. Limit of detection (µg/mL) 3.56 3.10 
8. Limit of quantification (µg/mL) 10.78 9.41 
9. Precision (%RSD) 
 
Intraday=0.2008 
Interday=0.976  
Intraday=0.164 
Interday=0.834 
10. Solution stability 
>12 hours 
Stable up to 24 hours 
%RSD=0.653 
Stable up to 24 hours 
%RSD=0.756 
11. Robustness (%RSD) complies Complies 
Flow plus 0.350 0.103 
Flow minus 0.338 0.207 
Organic plus 0.273 0.107 
Organic minus 0.364 0.279 
Wavelength plus 0.220 0.116 
Wavelength minus 0.146 0.199 
 
Table 3. Results of recovery study by HPLC methods. 
Method Drug Amt. present (µg/mL) Amt. spiked (µg/mL) % Recovery* 
HPLC 
method 
 
RAC 80 100 99.99 
100 100 100.00 
120 100 100.2 
OFL 160 200 99.42 
200 200 100.6 
240 200 100.64 
 
Table 4. Assay of marketed formulation RACIGYL-O by HPLC methods 
Drug Label claim (mg) Amount found (mg) %Assay  
RAC 100 100.009 100.02 
OFL 200 200.012 100.12 
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CONCLUSION 
Simple, rapid, accurate and precise RP-HPLC methods have 
been developed and validated for the routine analysis of RAC 
and OFL in API and capsules dosage forms. The methods are 
suitable for the simultaneous determination of RAC and OFL 
in multi-component formulations without interference of 
each other. The developed methods are suggested for routine 
and quality control analysis of the investigated drugs in 
pharmaceutical preparations. The amount found from the 
proposed methods was in good conformity with the label 
claim of the formulation. Also the value of standard deviation 
and coefficient of variation calculated were acceptably low, 
indicating the suitability of the proposed methods for the 
routine estimation of tablets dosage forms.  
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